Innate Pharma to join Jefferies Global Healthcare 2026

Accepted by SEC EDGAR 05/19/2026 - 06:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Innate Pharma S.A., a clinical-stage biotechnology company focused on cancer immunotherapies, filed a Form 6-K to share that its executive team will participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference 2026 in New York from June 2–4, 2026.

The company highlights its pipeline of potential first- or best-in-class antibody-based therapies, including IPH4502 for solid tumors, lacutamab for T-cell lymphomas, and monalizumab, which is being developed with AstraZeneca for non-small cell lung cancer. Innate also notes broader collaborations with partners such as Sanofi and AstraZeneca and its listings on Euronext Paris and Nasdaq.

Key Terms

clinical-stage biotechnology company, immunotherapies, Nectin-4 ADC, cutaneus T cell lymphomas, +1 more

5 terms

clinical-stage biotechnology company financial

"Innate Pharma SA ... a clinical-stage biotechnology company developing immunotherapies for cancer patients"

immunotherapies medical

"a clinical-stage biotechnology company developing immunotherapies for cancer patients"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

Nectin-4 ADC medical

"IPH4502, a differentiated Nectin-4 ADC developed in solid tumors"

cutaneus T cell lymphomas medical

"lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas"

non-small cell lung cancer medical

"monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer"

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Innate Pharma (IPHA) announce in this Form 6-K?

Innate Pharma announced its executive team will participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference 2026 in New York, highlighting ongoing outreach to investors and interest in its cancer immunotherapy pipeline.

When and where will Innate Pharma attend the Jefferies Global Healthcare Conference 2026?

Innate Pharma will attend the Jefferies Global Healthcare Conference 2026 in New York, United States, from June 2 to June 4, 2026, with executives scheduled for one-on-one investor meetings during the event.

What kind of company is Innate Pharma (IPHA) according to the filing?

Innate Pharma is described as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients, leveraging antibody-engineering expertise and innovative target identification to create next-generation antibody therapeutics with a focus on areas of high unmet medical need.

Which key drug candidates does Innate Pharma highlight in this report?

Innate Pharma highlights IPH4502, a differentiated Nectin-4 ADC for solid tumors, lacutamab, an anti-KIR3DL2 antibody for T-cell lymphomas, and monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer, as core assets in its oncology pipeline.

What major collaborations does Innate Pharma mention in the 6-K content?

Innate Pharma notes collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as partnerships with academic and research institutions, to advance innovation in immuno-oncology and support the development of its antibody-based cancer therapies.

On which stock exchanges are Innate Pharma shares listed?

Innate Pharma shares are listed on Euronext Paris under ticker IPH and on the Nasdaq exchange in the United States under ticker IPHA, reflecting its dual listing in Europe and the U.S. equity markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: Tuesday May 19, 2026

Commission File Number: 001-39084

Innate Pharma S.A.

(Translation of registrant's name into English)

Innate Pharma S.A.

117 Avenue de Luminy—BP 30191

13009 Marseille, France

+ 33 (0) 4 30 30 30

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]    Form 40-F [ ]

EXHIBIT INDEX

Exhibit Description

99.1 Press Release dated May 19, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNATE PHARMA S.A.

Date: May 19, 2026    By:    /s/ JONATHAN DICKINSON     Name:    Jonathan Dickinson

Title:    Chief Executive officer

EXHIBIT 99.1

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Marseille, France, May 19, 2026, 7:00 AM CEST

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in one-on-one investor meetings at the following conference:

Jefferies Global Healthcare Conference 2026

Dates: June 2–4, 2026

Location: New York, United States

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code FR0010331421

Ticker code Euronext: IPH Nasdaq: IPHA

LEI    9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors & Media Relations

Innate Pharma

Stéphanie Cornen

stephanie.cornen@innate-pharma.fr

Investor Relations

investors@innate-pharma.fr

Media

communication@innate-pharma.fr

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 11.1 KB